June 22, 2026

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE

To all stakeholders,

(Amendments) Amendments to "Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2026"

Perseus Proteomics Inc. ("the Company") hereby announces amendments to "Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2026" announced on May 14, 2026. The amended parts are underlined.

1. Reasons for amendments

   The Company has found some errors in "Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2026" after submission and now makes amendments.

2. Amendment details

(1) Page 8 2. Non-consolidated financial statements (3) Statement of cash flows

(Before amendment)

(thousand yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from operating activities		
Loss before income taxes	(902,340)	(716,181)
Depreciation and amortization	2,846	382
Impairment losses	72,510	37,260
Interest income	(1,951)	(5,044)
Subsidy income	-	(53,311)
Share issuance costs	4,233	6,398
Share-based payment expenses	6,592	-
Decrease (increase) in trade receivables	(8,554)	4,090
Decrease (increase) in inventories	(906)	(1,805)
Decrease (increase) in advance payments - trade	(17)	-
Increase (decrease) in accounts payable - other	8,171	(34,767)
Increase (decrease) in long-term deposits	95,077	78,765
Other, net	4,819	(24,191)
Subtotal	(719,517)	(708,403)
Interest received	1,952	4,627
Subsidies received	-	53,311
Income taxes paid	(1,927)	(3,168)
Income taxes refund	6	299
Net cash flows provided by (used in) operating activities	(719,485)	(653,334)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
		(thousand yen)
Cash flows from investing activities		
Purchase of property, plant and equipment	(75,157)	(9,494)
Purchase of intangible assets	-	(450)
Payments of guarantee deposits	-	(118)
Net cash flows provided by (used in) investing activities	(75,157)	(10,062)
Cash flows from financing activities		
Expenses from issuance of shares	(4,359)	(97)
Proceeds from issuance of shares resulting from exercise of share acquisition rights	932,269	500,500
Proceeds from issuance of share acquisition rights	-	2,980
Payments for issuance of subscription rights to shares	(4,528)	(6,040)
Purchase of treasury shares	-	(9)
Net cash flows provided by (used in) financing activities	923,381	497,333
Effect of exchange rate change on cash and cash equivalents	2,237	13,489
Net increase (decrease) in cash and cash equivalents	126,501	(152,574)
Cash and cash equivalents at beginning of period	1,541,419	1,667,921
Cash and cash equivalents at end of period	1,667,921	1,515,346

(After amendment)

(thousand yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from operating activities		
Loss before income taxes	(902,340)	(716,181)
Depreciation and amortization	2,846	382
Impairment losses	72,510	37,260
Interest income	(1,951)	(5,044)
Subsidy income	-	(53,311)
Share issuance costs	4,233	6,398
Share-based payment expenses	6,592	-
Decrease (increase) in trade receivables	(8,554)	4,090
Decrease (increase) in inventories	(906)	(1,805)
Decrease (increase) in advance payments - trade	(17)	-
Increase (decrease) in accounts payable - other	8,171	(34,767)
Increase (decrease) in long-term deposits	95,077	78,765
Other, net	4,819	(24,191)
Subtotal	(719,517)	(708,403)
Interest received	1,952	4,627
Subsidies received	-	53,311
Income taxes paid	(1,927)	(3,168)
Income taxes refund	6	299
Net cash flows provided by (used in) operating activities	(719,485)	(653,334)
Cash flows from investing activities		
Purchase of property, plant and equipment	(75,157)	(9,264)
Purchase of intangible assets	-	(680)
Payments of guarantee deposits	-	(118)
Net cash flows provided by (used in) investing activities	(75,157)	(10,062)

(thousand yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from financing activities		
Expenses from issuance of shares	(4,359)	(97)
Proceeds from issuance of shares resulting from exercise of share acquisition rights	932,269	500,500
Proceeds from issuance of share acquisition rights	-	2,980
Payments for issuance of subscription rights to shares	(4,528)	(6,040)
Purchase of treasury shares	-	(9)
Net cash flows provided by (used in) financing activities	923,381	497,333
Effect of exchange rate change on cash and cash equivalents	2,237	13,489
Net increase (decrease) in cash and cash equivalents	126,501	(152,574)
Cash and cash equivalents at beginning of period	1,541,419	1,667,921
Cash and cash equivalents at end of period	1,667,921	1,515,346

END